Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$336.79
+0.1%
$342.53
$267.83
$391.29
$181.60B0.442.53 million shs2.95 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,105.37
-1.9%
$955.92
$623.78
$1,149.10
$1.06T0.483.09 million shs4.60 million shs
Stryker Corporation stock logo
SYK
Stryker
$305.73
-0.6%
$321.82
$281.00
$404.87
$117.93B0.82.96 million shs6.06 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+0.12%-0.28%-0.91%-13.31%+20.86%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+3.81%+8.14%+28.89%+7.26%+56.79%
Stryker Corporation stock logo
SYK
Stryker
+0.35%-2.00%-4.41%-20.68%-19.20%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$336.79
+0.1%
$342.53
$267.83
$391.29
$181.60B0.442.53 million shs2.95 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,105.37
-1.9%
$955.92
$623.78
$1,149.10
$1.06T0.483.09 million shs4.60 million shs
Stryker Corporation stock logo
SYK
Stryker
$305.73
-0.6%
$321.82
$281.00
$404.87
$117.93B0.82.96 million shs6.06 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+0.12%-0.28%-0.91%-13.31%+20.86%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+3.81%+8.14%+28.89%+7.26%+56.79%
Stryker Corporation stock logo
SYK
Stryker
+0.35%-2.00%-4.41%-20.68%-19.20%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.48
Hold$355.195.46% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,227.0011.00% Upside
Stryker Corporation stock logo
SYK
Stryker
2.73
Moderate Buy$395.4829.35% Upside

Current Analyst Ratings Breakdown

Latest LLY, AMGN, and SYK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,133.00 ➝ $1,251.00
5/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Set Price Target$1,119.00
5/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,283.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,350.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$1,300.00 ➝ $1,330.00
5/20/2026
Amgen Inc. stock logo
AMGN
Amgen
Lower Price TargetBuy$400.00 ➝ $375.00
5/19/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy (B)Buy (B-)
5/14/2026
Amgen Inc. stock logo
AMGN
Amgen
Lower Price TargetOverweight$432.00 ➝ $427.00
5/13/2026
Amgen Inc. stock logo
AMGN
Amgen
Lower Price TargetOutperform$410.00 ➝ $390.00
5/7/2026
Amgen Inc. stock logo
AMGN
Amgen
UpgradeHoldStrong-Buy
(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$36.75B4.95$33.85 per share9.95$17.03 per share19.78
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B15.97$24.66 per share44.83$33.13 per share33.36
Stryker Corporation stock logo
SYK
Stryker
$25.27B4.64$16.79 per share18.21$59.94 per share5.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$14.3723.4414.293.3820.96%137.41%13.28%8/4/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1539.2724.941.2334.98%105.77%23.76%8/5/2026 (Estimated)
Stryker Corporation stock logo
SYK
Stryker
$3.25B$8.6435.3918.381.9413.20%23.42%11.04%7/30/2026 (Estimated)

Latest LLY, AMGN, and SYK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2026Q1 2026
Amgen Inc. stock logo
AMGN
Amgen
$4.77$5.15+$0.38$3.34$8.58 billion$8.62 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/30/2026Q1 2026
Stryker Corporation stock logo
SYK
Stryker
$2.98$2.60-$0.38$1.93$6.34 billion$6.02 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$10.082.99%+8.27%70.15%14 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.63%+15.18%24.58%11 Years
Stryker Corporation stock logo
SYK
Stryker
$3.521.15%+7.58%40.74%32 Years

Latest LLY, AMGN, and SYK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2026
Stryker Corporation stock logo
SYK
Stryker
quarterly$0.881.2%6/30/20266/30/20267/31/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
3/4/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.523.09%5/15/20265/15/20266/5/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
5.65
1.26
1.01
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Stryker Corporation stock logo
SYK
Stryker
0.62
2.11
1.25

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Stryker Corporation stock logo
SYK
Stryker
77.09%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Stryker Corporation stock logo
SYK
Stryker
4.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500539.71 million535.12 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Stryker Corporation stock logo
SYK
Stryker
56,000383.36 million365.73 millionOptionable

Recent News About These Companies

Stryker: Reaching Interesting Levels
Stryker - Reaching Interesting Levels

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amgen stock logo

Amgen NASDAQ:AMGN

$336.79 +0.31 (+0.09%)
Closing price 04:00 PM Eastern
Extended Trading
$336.71 -0.08 (-0.02%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,105.37 -21.43 (-1.90%)
Closing price 03:59 PM Eastern
Extended Trading
$1,105.00 -0.37 (-0.03%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Stryker stock logo

Stryker NYSE:SYK

$305.73 -1.90 (-0.62%)
Closing price 03:59 PM Eastern
Extended Trading
$306.46 +0.73 (+0.24%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.